Doxorubicin Accord Healthcare 2 mg/ml solution à diluer pour perfusion

DRUG2 trials

Sponsors

Institut Curie, Institut Curie, Lysarc

Conditions

Early and metastatic triple negative breast cancerPeripheral T-cell lymphoma (PTCL)

Phase 2

"SKYLINE": Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer: A phase II trial

RecruitingCTIS2022-501561-51-00

Institut Curie, Institut CurieEarly and metastatic triple negative breast cancer

Start: 2024-03-27Target: 160Updated: 2025-05-07

Phase 4

TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma

RecruitingCTIS2022-501710-62-02

LysarcPeripheral T-cell lymphoma (PTCL)

Start: 2023-06-07Target: 204Updated: 2026-01-19